Nonalcoholic fatty liver disease (NAFLD) including nonalcoholic fatty liver, nonalcoholic steatohepatitis, fibrosis, cirrhosis, and eventually hepatocellular carcinoma has become the most common liver disease worldwide. The global prevalence of NAFLD is currently estimated to be 25.2%. The pathogenesis of NAFLD is complicated which are associated with diet, genetic, environment and metabolic factors. No approved pharmacological options are available for NAFLD currently. Along with the development of analytical and phytochemical technology, more and more phytochemicals with clear chemical structure have been found with the potential to treat NAFLD.
This Research Topic aims to investigate the novel discovery of molecular pathogenic mechanisms of NAFLD using multiomics. Simultaneously, novel findings on phytochemicals with clear chemical structure from traditional medical herbs, or natural plants, or novel natural compounds, active ingredients that can be used for NAFLD are welcome.
The Topic Editors welcome original research articles, reviews, opinions, and perspective articles including but not limited to the following themes:
- Research on the pathogenesis of NAFLD based on omics technology, such as genomics, transcriptomics, proteomics, metagenomics, and metabolomics, including hepatic steatosis, hepatitis, hepatic fibrosis, cirrhosis, and hepatocellular carcinoma.
- Research on underlying pharmacological mechanism from phytochemicals with clear chemical structure from traditional medical herbs, natural plants, or novel natural compounds, active ingredients, combination formulas on prevention and treatment of NAFLD, based on omics technology, such as genomics, transcriptomics, proteomics, metagenomics, and metabolomics
Note to authors:
Studies carried out with crude extracts/multiherbal preparations will not be considered for review. In contrast, studies which utilize highly purified, chemically characterized compounds meet the minimum criteria for investigation of pharmacological effect.
Where extracts are claimed to meet such minimum criteria, chemical structure and purity must be precisely described by appropriate analytical methods (e.g. chromatography and/or mass spectrometry).
Original research based solely on in silico techniques will not be considered for review.
Following the general standards for Frontiers in Pharmacology, effect in a minimum of 2 cell-lines in vitro is the minimum evidential basis to demonstrate proposed anti-cancer effect in all relevant submissions.
Nonalcoholic fatty liver disease (NAFLD) including nonalcoholic fatty liver, nonalcoholic steatohepatitis, fibrosis, cirrhosis, and eventually hepatocellular carcinoma has become the most common liver disease worldwide. The global prevalence of NAFLD is currently estimated to be 25.2%. The pathogenesis of NAFLD is complicated which are associated with diet, genetic, environment and metabolic factors. No approved pharmacological options are available for NAFLD currently. Along with the development of analytical and phytochemical technology, more and more phytochemicals with clear chemical structure have been found with the potential to treat NAFLD.
This Research Topic aims to investigate the novel discovery of molecular pathogenic mechanisms of NAFLD using multiomics. Simultaneously, novel findings on phytochemicals with clear chemical structure from traditional medical herbs, or natural plants, or novel natural compounds, active ingredients that can be used for NAFLD are welcome.
The Topic Editors welcome original research articles, reviews, opinions, and perspective articles including but not limited to the following themes:
- Research on the pathogenesis of NAFLD based on omics technology, such as genomics, transcriptomics, proteomics, metagenomics, and metabolomics, including hepatic steatosis, hepatitis, hepatic fibrosis, cirrhosis, and hepatocellular carcinoma.
- Research on underlying pharmacological mechanism from phytochemicals with clear chemical structure from traditional medical herbs, natural plants, or novel natural compounds, active ingredients, combination formulas on prevention and treatment of NAFLD, based on omics technology, such as genomics, transcriptomics, proteomics, metagenomics, and metabolomics
Note to authors:
Studies carried out with crude extracts/multiherbal preparations will not be considered for review. In contrast, studies which utilize highly purified, chemically characterized compounds meet the minimum criteria for investigation of pharmacological effect.
Where extracts are claimed to meet such minimum criteria, chemical structure and purity must be precisely described by appropriate analytical methods (e.g. chromatography and/or mass spectrometry).
Original research based solely on in silico techniques will not be considered for review.
Following the general standards for Frontiers in Pharmacology, effect in a minimum of 2 cell-lines in vitro is the minimum evidential basis to demonstrate proposed anti-cancer effect in all relevant submissions.